Cellular Immunotherapy for Malignant Brain Tumors

[1]  F. Quintana,et al.  Tolerogenic dendritic cells , 2016, Seminars in Immunopathology.

[2]  G. Rho,et al.  Characterization and comparison of telomere length, telomerase and reverse transcriptase activity and gene expression in human mesenchymal stem cells and cancer cells of various origins , 2011, Cell and Tissue Research.

[3]  J. Sampson,et al.  Is Cytomegalovirus a Therapeutic Target in Glioblastoma? , 2011, Clinical Cancer Research.

[4]  R. McLendon,et al.  A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  R. McLendon,et al.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. , 2011, Neuro-oncology.

[6]  H. Ueno,et al.  Recent Developments in Cancer Vaccines , 2011, The Journal of Immunology.

[7]  D. Nam,et al.  Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression , 2011, Molecules and cells.

[8]  H. Ueno,et al.  Dendritic cells and immunity against cancer , 2011, Journal of internal medicine.

[9]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[10]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. D. de Groot,et al.  Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[12]  R. Yamanaka.  Dendritic-cell- and peptide-based vaccination strategies for glioma , 2009, Neurosurgical Review.

[13]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[14]  H. Ueno,et al.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. , 2008, Immunity.

[15]  K. Black,et al.  Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. , 2008, Cancer research.

[16]  Mitchel S Berger,et al.  Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. , 2008, Neuro-oncology.

[17]  R. Sciot,et al.  Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[18]  J. Sampson,et al.  Immunotherapy of malignant brain tumors , 2008, Immunological reviews.

[19]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[20]  R. Coleman,et al.  A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. , 2008, Neuro-oncology.

[21]  K. Aldape,et al.  Detection of human cytomegalovirus in different histological types of gliomas , 2008, Acta Neuropathologica.

[22]  P. Walker,et al.  Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells , 2008, The Journal of Immunology.

[23]  W. Debinski,et al.  Interleukin-13 Receptor α2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy , 2008, Clinical Cancer Research.

[24]  R. Coleman,et al.  Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 , 2007, Journal of Nuclear Medicine.

[25]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[27]  R. Steinman,et al.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. , 2007, The Journal of clinical investigation.

[28]  M Kiessling,et al.  Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma , 2007, International journal of cancer.

[29]  L. Boon,et al.  CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo , 2007, International journal of cancer.

[30]  John E. Connolly,et al.  IL‐15‐induced human DC efficiently prime melanoma‐specific naive CD8+ T cells to differentiate into CTL , 2007, European journal of immunology.

[31]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[32]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[33]  S. Rosenberg,et al.  Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. , 2007, The Journal of clinical investigation.

[34]  S. Stevanović,et al.  Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11. , 2007, Cancer letters.

[35]  I. Bechmann,et al.  T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa , 2006, Journal of leukocyte biology.

[36]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[37]  D. Bigner,et al.  Systemic Anti-CD25 Monoclonal Antibody Administration Safely Enhances Immunity in Murine Glioma without Eliminating Regulatory T Cells , 2006, Clinical Cancer Research.

[38]  Lieping Chen,et al.  Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. , 2006, Trends in molecular medicine.

[39]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[40]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[41]  L. Liau,et al.  The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity1 , 2006, The Journal of Immunology.

[42]  J. Cheville,et al.  B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. , 2005, Urology.

[43]  M. Shigemori,et al.  Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma , 2005, Clinical Cancer Research.

[44]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[45]  Naoto Tsuchiya,et al.  Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[47]  F. Marincola,et al.  Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, ΔEGF-R, and de2–7 EGF-R)1 , 2004, The Journal of Immunology.

[48]  D. Kufe,et al.  Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12 , 2004, Journal of immunotherapy.

[49]  P. Flamen,et al.  Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study , 2004, British Journal of Cancer.

[50]  R. Mikkelsen,et al.  Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity , 2004, Clinical Cancer Research.

[51]  R. Dillman,et al.  Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma , 2004, Journal of immunotherapy.

[52]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[53]  Keith L. Black,et al.  Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma , 2004, Cancer Research.

[54]  A. M. Neale,et al.  Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. , 2004, Neuro-oncology.

[55]  M. Weller,et al.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.

[56]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[57]  H. Fujii,et al.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  R. Tanaka,et al.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial , 2003, British Journal of Cancer.

[59]  T. Di Pucchio,et al.  Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-α , 2003, The Journal of experimental medicine.

[60]  H. Katoh,et al.  Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in vivo , 2003, International journal of cancer.

[61]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[62]  H. Groux,et al.  Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. , 2003, Immunity.

[63]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  K. Tung,et al.  Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. , 2002, International immunology.

[65]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[66]  F. Marincola,et al.  Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. , 2002, Cancer research.

[67]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[68]  R. Steinman,et al.  Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. , 2002, Blood.

[69]  A. Coutinho,et al.  Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Das,et al.  Expression of survivin in primary glioblastomas , 2002, Journal of Cancer Research and Clinical Oncology.

[71]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Y. Kondo,et al.  Telomerase as a therapeutic target for malignant gliomas , 2002, Oncogene.

[74]  L. Ignatowicz,et al.  Peptide Specificity of Thymic Selection of CD4+CD25+ T Cells , 2002, The Journal of Immunology.

[75]  R. Lechler,et al.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. , 2001, Blood.

[76]  C. Fathman,et al.  CD4+CD25+ T Cells Facilitate the Induction of T Cell Anergy , 2001, The Journal of Immunology.

[77]  S. Agrawal,et al.  Survivin inhibition induces human neural tumor cell death through caspase‐independent and ‐dependent pathways , 2001, Journal of neurochemistry.

[78]  T. Ohno,et al.  Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells , 2001, Cancer Immunology, Immunotherapy.

[79]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[80]  K. Yudoh,et al.  Effects of Vascular Endothelial Growth Factor and E-Selectin on Angiogenesis in the Murine Metastatic RCT Sarcoma , 2001, Tumor Biology.

[81]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[82]  D Pinkel,et al.  High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. , 2001, Human molecular genetics.

[83]  A. Friedman,et al.  Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[84]  D. O’Rourke,et al.  Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters β-Tubulin Isotype Expression* , 2000, The Journal of Biological Chemistry.

[85]  L. Adorini,et al.  Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. , 2000, Immunology today.

[86]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[87]  Simon C Watkins,et al.  Maturation and Trafficking of Monocyte-Derived Dendritic Cells in Monkeys: Implications for Dendritic Cell-Based Vaccines1 , 2000, The Journal of Immunology.

[88]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[89]  E. Gilboa,et al.  Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.

[90]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  S. Powers,et al.  Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. , 1999, International journal of oncology.

[92]  R. McLendon,et al.  Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  F. Otsuka,et al.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.

[94]  K. Saijo,et al.  Reduction of End‐stage Malignant Glioma by Injection with Autologous Cytotoxic T Lymphocytes , 1999, Japanese journal of cancer research : Gann.

[95]  D. Bigner,et al.  Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. , 1999, Nuclear medicine and biology.

[96]  D. Mason,et al.  Regulatory T Cells in the Control of Autoimmunity: the Essential Role of  Transforming Growth Factor β and Interleukin 4 in the Prevention of Autoimmune Thyroiditis in Rats by Peripheral CD4+CD45RC− Cells and CD4+CD8− Thymocytes , 1999, The Journal of experimental medicine.

[97]  W. Hickey,et al.  Humoral immunity in the central nervous system of Lewis rats infected with Borna disease virus , 1998, Journal of Neuroimmunology.

[98]  W. Hickey,et al.  Evolution of the immune response in the central nervous system following infection with Borna disease virus , 1998, Journal of Neuroimmunology.

[99]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[100]  R. Coleman,et al.  Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  J. Sedgwick,et al.  Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts. , 1998, Journal of immunology.

[102]  T. Roszman,et al.  T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. , 1997, Journal of immunology.

[103]  D. Bigner,et al.  In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. , 1997, Nuclear medicine and biology.

[104]  J. Stears,et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.

[105]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[106]  M. Béné,et al.  Ultrastructural and immunohistological evidence for dendritic‐like cells within human choroid plexus epithelium , 1997, Neuroreport.

[107]  K. Shroyer,et al.  Differential telomerase expression in human primary intracranial tumors. , 1997, American journal of clinical pathology.

[108]  L. Falo,et al.  Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. , 1997, The Journal of investigative dermatology.

[109]  D. Bigner,et al.  Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. , 1997, Cancer research.

[110]  J. Kononen,et al.  Short Communication Increased Expression of Telomerase RNA Component Is Associated with Increased Cell Proliferation in Human Astrocytomas , 2007 .

[111]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[112]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[113]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[114]  J. Sedgwick,et al.  Microglia induce CD4 T lymphocyte final effector function and death , 1996, The Journal of experimental medicine.

[115]  H. Pircher,et al.  On the role of antigen in maintaining cytotoxic T-cell memory. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[116]  H. Magdelenat,et al.  A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. , 1996, Neurosurgery.

[117]  S. Sakaguchi,et al.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation , 1996, The Journal of experimental medicine.

[118]  B. Engelhardt,et al.  Lymphocyte Targeting of the Central Nervous System: A Review of Afferent and Efferent CNS‐Immune Pathways , 1996, Brain pathology.

[119]  R. Coleman,et al.  Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  G. Stragliotto,et al.  Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. , 1996, European journal of cancer.

[121]  H. Wekerle,et al.  The Shaping of the Brain–Specific T Lymphocyte Repertoire in the Thymus , 1996, Immunological reviews.

[122]  R. McLendon,et al.  Tumor antigens in astrocytic gliomas , 1995, Glia.

[123]  M. Willingham,et al.  Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. , 1995, Cancer research.

[124]  P. Humphrey,et al.  Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[125]  H. Hochster,et al.  Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma , 1995, Cancer.

[126]  I. Pastan,et al.  Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[127]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[128]  G. Kreutzberg,et al.  Microglia: Intrinsic immuneffector cell of the brain , 1995, Brain Research Reviews.

[129]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[130]  M. Hart,et al.  Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. , 1994, Immunology today.

[131]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[132]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[133]  A. Blancher,et al.  Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. , 1993, European cytokine network.

[134]  T. Turkington,et al.  Measuring astatine-211 distributions with SPECT. , 1993, Physics in medicine and biology.

[135]  E. Jeffes,et al.  Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA , 1993, Journal of Neuro-Oncology.

[136]  P. Knopf,et al.  Drainage of Brain Extracellular Fluid into Blood and Deep Cervical Lymph and its Immunological Significance , 1992, Brain pathology.

[137]  R. Merchant,et al.  In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect. , 1992, Journal of neurosurgery.

[138]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[139]  P. Humphrey,et al.  Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. , 1990, Cancer research.

[140]  J. Buckwalter,et al.  Immunotherapy for recurrent malignant glioma: an interim report on survival. , 1990, Neurological research.

[141]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[142]  P. Humphrey,et al.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[143]  H. Koeppen,et al.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[144]  P. Knopf,et al.  Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid , 1989, Journal of Neuroimmunology.

[145]  R. Merchant,et al.  Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. , 1988, Neurosurgery.

[146]  S. Rosenberg.  The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin‐2: A Review , 1988, Annals of surgery.

[147]  H. Boehmer,et al.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes , 1988, Nature.

[148]  A. Roberts,et al.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. , 1988, Journal of immunology.

[149]  W. Hickey,et al.  Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. , 1988, Science.

[150]  B. Haendler,et al.  Complementary DNA for human glioblastoma‐derived T cell suppressor factor, a novel member of the transforming growth factor‐beta gene family. , 1987, The EMBO journal.

[151]  P. Marrack,et al.  T cell tolerance by clonal elimination in the thymus , 1987, Cell.

[152]  M. Sporn,et al.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. , 1986, Journal of immunology.

[153]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.

[154]  S. Jacobs,et al.  Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. , 1986, Cancer research.

[155]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[156]  P. Steinbok,et al.  Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme , 1984, Journal of Neuro-Oncology.

[157]  T. Roszman,et al.  Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. , 1984, Journal of immunology.

[158]  T. Roszman,et al.  Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. , 1980, Clinical and experimental immunology.

[159]  N. Di Lorenzo,et al.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. , 1978, Journal of neurosurgery.

[160]  W. Markesbery,et al.  Relationship of lymphocyte invasion and survival of brain tumor patients , 1978, Annals of neurology.

[161]  W. Regelson,et al.  Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme. A preliminary report , 1977, Cancer.

[162]  A. Heimberger,et al.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? , 2011, Neuro-oncology.

[163]  H. Lowman,et al.  Therapeutic anti-VEGF antibodies. , 2008, Handbook of experimental pharmacology.

[164]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[165]  M. Sailer,et al.  Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. , 2006, Journal of neuro-oncology.

[166]  R. Puri,et al.  IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. , 2006, Nature medicine.

[167]  R. Coleman,et al.  Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  G. Schackert,et al.  Activated monocytes kill malignant brain tumor cellsin vitro , 2005, Journal of Neuro-Oncology.

[169]  G. Suzuki,et al.  Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor , 2004, Journal of Neuro-Oncology.

[170]  M. Varia,et al.  Pilot Study of Local Autologous Tumor Infiltrating Lymphocytes for the Treatment of Recurrent Malignant Gliomas , 2004, Journal of Neuro-Oncology.

[171]  J. Hallett,et al.  Hierarchy of immune responses to antigen in the normal brain. , 2002, Current topics in microbiology and immunology.

[172]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[173]  D. Carbone,et al.  VEGF as a mediator of tumor-associated immunodeficiency , 2001, Immunologic research.

[174]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[175]  K. Lillehei,et al.  Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. , 1991, Neurosurgery.

[176]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[177]  E. Grimm,et al.  Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system. , 1989, Immunology series.

[178]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.